The dysregulation of exosomal microRNAs(miRNAs)plays a crucial role in the development and progression of cancer.This study investigated the role of a newly identified serum exosomal miRNA miR-4256 in gastric cancer(G...The dysregulation of exosomal microRNAs(miRNAs)plays a crucial role in the development and progression of cancer.This study investigated the role of a newly identified serum exosomal miRNA miR-4256 in gastric cancer(GC)and the underlying mechanisms.The differentially expressed miRNAs were firstly identified in serum exosomes of GC patients and healthy individuals using next-generation sequencing and bioinformatics.Next,the expression of serum exosomal miR-4256 was analyzed in GC cells and GC tissues,and the role of miR-4256 in GC was investigated by in vitro and in vivo experiments.Then,the effect of miR-4256 on its downstream target genes HDAC5/p16^(INK4a) was studied in GC cells,and the underlying mechanisms were evaluated using dual luciferase reporter assay and Chromatin Immunoprecipitation(ChIP).Additionally,the role of the miR-4256/HDAC5/p16^(INK4a) axis in GC was studied using in vitro and in vivo experiments.Finally,the upstream regulators SMAD2/p300 that regulate miR-4256 expression and their role in GC were explored using in vitro experiments.miR-4256 was the most significantly upregulated miRNA and was overexpressed in GC cell lines and GC tissues;in vitro and in vivo results showed that miR-4256 promoted GC growth and progression.Mechanistically,miR-4256 enhanced HDAC5 expression by targeting the promoter of the HDAC5 gene in GC cells,and then restrained the expression of p16^(INK4a) through the epigenetic modulation of HDAC5 at the p16INK4a promoter.Furthermore,miR-4256 overexpression was positively regulated by the SMAD2/p300 complex in GC cells.Our data indicate that miR-4256 functions as an oncogene in GC via the SMAD2/miR-4256/HDAC5/p16^(INK4a) axis,which participates in GC progression and provides novel therapeutic and prognostic biomarkers for GC.展开更多
目的:观察黄芪甲苷(AS-IV)通过调控蛋白激酶D1(PKD1)-组蛋白脱乙酰酶5(HDAC5)-血管内皮生长因子(VEGF)信号通路促心肌梗死大鼠血管新生的作用并分析其可能的作用机制。方法:采用经典的左冠状动脉前降支结扎术复制心肌梗死模型后,将大鼠...目的:观察黄芪甲苷(AS-IV)通过调控蛋白激酶D1(PKD1)-组蛋白脱乙酰酶5(HDAC5)-血管内皮生长因子(VEGF)信号通路促心肌梗死大鼠血管新生的作用并分析其可能的作用机制。方法:采用经典的左冠状动脉前降支结扎术复制心肌梗死模型后,将大鼠分成模型组、AS-IV治疗组和AS-IV+CID755673(PKD1阻断剂)组,另设假手术对照组和二甲基亚砜(DMSO)对照组,均采用尾静脉注射的给药方式。4周后处死大鼠,应用HE染色和Masson染色分析左心室心肌组织病理学变化;应用RT-PCR分析心肌组织中PKD1、HDAC5和VEGF m RNA的表达;免疫组化及Western blot法分析心肌组织中PKD1、VEGF及HDAC5蛋白的表达。结果:组织病理学分析表明,假手术组和DMSO组大鼠心肌组织形态正常,而模型组大鼠心肌组织形态紊乱,心肌细胞坏死和纤维化明显;AS-IV治疗后,心肌组织形态改善明显,且新生的血管数量明显增多;AS-IV+CID755673处理后大鼠心肌组织形态再次趋向紊乱,坏死细胞增多,部分血管闭合。模型组心肌组织中PKD1、HDAC5和VEGF的m RNA和蛋白表达明显低于假手术组和DMSO组(P<0.05),而AS-IV组显著高于模型组(P<0.01),AS-IV+CID755673组明显低于AS-IV组(P<0.05)。结论:AS-IV可部分通过调控PKD1-HDAC5-VEGF信号通路发挥促大鼠心肌梗死后心肌组织血管新生的作用。展开更多
The reduced expression of miR-142-3p/5p in CD4^(+) T cells of SLE patients caused T cell hyperactivity and B cell hyperstimulation.This study aimed to investigate the mechanisms of regulating miR-142-3p/5p expression ...The reduced expression of miR-142-3p/5p in CD4^(+) T cells of SLE patients caused T cell hyperactivity and B cell hyperstimulation.This study aimed to investigate the mechanisms of regulating miR-142-3p/5p expression in SLE CD4^(+) T cells.The BCL-6 expression was significantly increased in SLE CD4^(+) T cells compared with normal controls,and the BCL-6 expression was inversely correlated with miR-142-3p/5p expression.BCL-6 suppresses the expression of miR-142-3p/5p by increasing H3K27me3 level and reducing H3K9/K14ac levels in SLE CD4^(+) T cells.BCL-6 regulates histone modifications in miR-142 promoter by recruiting EZH2 and HDAC5.Furthermore,we observed significantly decreased CD40L,ICOS,and IL-21 expression levels in SLE CD4^(+) T cells with BCL-6 interference,and obviously reduced autoantibody IgG production in autologous B cells co-cultured with BCL-6 inhibited SLE CD4^(+) T cells.Our study found that increased BCL-6 up-regulates H3K27me3 and down-regulates H3K9/14ac at miR-142 promoter in SLE CD4^(+) T cells.These factors induce a declination in miR-142-3p/5p expression,consequently resulting in CD4^(+) T cell hyperactivity.展开更多
基金The studies involving human participants were approved by The First Affiliated Hospital of Jinan University Ethics Committee(KY-2021-095)The participants provided their written informed consent to participate in this study+1 种基金Animalinvolved experimental protocols were compliance with guidelines and licensesapproved by the Laboratory Animal Center of Jinan University(20220225-65).
文摘The dysregulation of exosomal microRNAs(miRNAs)plays a crucial role in the development and progression of cancer.This study investigated the role of a newly identified serum exosomal miRNA miR-4256 in gastric cancer(GC)and the underlying mechanisms.The differentially expressed miRNAs were firstly identified in serum exosomes of GC patients and healthy individuals using next-generation sequencing and bioinformatics.Next,the expression of serum exosomal miR-4256 was analyzed in GC cells and GC tissues,and the role of miR-4256 in GC was investigated by in vitro and in vivo experiments.Then,the effect of miR-4256 on its downstream target genes HDAC5/p16^(INK4a) was studied in GC cells,and the underlying mechanisms were evaluated using dual luciferase reporter assay and Chromatin Immunoprecipitation(ChIP).Additionally,the role of the miR-4256/HDAC5/p16^(INK4a) axis in GC was studied using in vitro and in vivo experiments.Finally,the upstream regulators SMAD2/p300 that regulate miR-4256 expression and their role in GC were explored using in vitro experiments.miR-4256 was the most significantly upregulated miRNA and was overexpressed in GC cell lines and GC tissues;in vitro and in vivo results showed that miR-4256 promoted GC growth and progression.Mechanistically,miR-4256 enhanced HDAC5 expression by targeting the promoter of the HDAC5 gene in GC cells,and then restrained the expression of p16^(INK4a) through the epigenetic modulation of HDAC5 at the p16INK4a promoter.Furthermore,miR-4256 overexpression was positively regulated by the SMAD2/p300 complex in GC cells.Our data indicate that miR-4256 functions as an oncogene in GC via the SMAD2/miR-4256/HDAC5/p16^(INK4a) axis,which participates in GC progression and provides novel therapeutic and prognostic biomarkers for GC.
文摘目的:观察黄芪甲苷(AS-IV)通过调控蛋白激酶D1(PKD1)-组蛋白脱乙酰酶5(HDAC5)-血管内皮生长因子(VEGF)信号通路促心肌梗死大鼠血管新生的作用并分析其可能的作用机制。方法:采用经典的左冠状动脉前降支结扎术复制心肌梗死模型后,将大鼠分成模型组、AS-IV治疗组和AS-IV+CID755673(PKD1阻断剂)组,另设假手术对照组和二甲基亚砜(DMSO)对照组,均采用尾静脉注射的给药方式。4周后处死大鼠,应用HE染色和Masson染色分析左心室心肌组织病理学变化;应用RT-PCR分析心肌组织中PKD1、HDAC5和VEGF m RNA的表达;免疫组化及Western blot法分析心肌组织中PKD1、VEGF及HDAC5蛋白的表达。结果:组织病理学分析表明,假手术组和DMSO组大鼠心肌组织形态正常,而模型组大鼠心肌组织形态紊乱,心肌细胞坏死和纤维化明显;AS-IV治疗后,心肌组织形态改善明显,且新生的血管数量明显增多;AS-IV+CID755673处理后大鼠心肌组织形态再次趋向紊乱,坏死细胞增多,部分血管闭合。模型组心肌组织中PKD1、HDAC5和VEGF的m RNA和蛋白表达明显低于假手术组和DMSO组(P<0.05),而AS-IV组显著高于模型组(P<0.01),AS-IV+CID755673组明显低于AS-IV组(P<0.05)。结论:AS-IV可部分通过调控PKD1-HDAC5-VEGF信号通路发挥促大鼠心肌梗死后心肌组织血管新生的作用。
基金by the National Natural Science Foundation of China(No.81402610 and No.81502733).
文摘The reduced expression of miR-142-3p/5p in CD4^(+) T cells of SLE patients caused T cell hyperactivity and B cell hyperstimulation.This study aimed to investigate the mechanisms of regulating miR-142-3p/5p expression in SLE CD4^(+) T cells.The BCL-6 expression was significantly increased in SLE CD4^(+) T cells compared with normal controls,and the BCL-6 expression was inversely correlated with miR-142-3p/5p expression.BCL-6 suppresses the expression of miR-142-3p/5p by increasing H3K27me3 level and reducing H3K9/K14ac levels in SLE CD4^(+) T cells.BCL-6 regulates histone modifications in miR-142 promoter by recruiting EZH2 and HDAC5.Furthermore,we observed significantly decreased CD40L,ICOS,and IL-21 expression levels in SLE CD4^(+) T cells with BCL-6 interference,and obviously reduced autoantibody IgG production in autologous B cells co-cultured with BCL-6 inhibited SLE CD4^(+) T cells.Our study found that increased BCL-6 up-regulates H3K27me3 and down-regulates H3K9/14ac at miR-142 promoter in SLE CD4^(+) T cells.These factors induce a declination in miR-142-3p/5p expression,consequently resulting in CD4^(+) T cell hyperactivity.
